突破性疗法称号-话题@MedSci

#突破性疗法称号#

13篇内容 | 1055人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1949560, encodeId=33e71949560ad, content=<a href='/topic/show?id=ed1fe5540f0' target=_blank style='color:#2F92EE;'>#突破性疗法称号#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, objectType=article, longId=221117, objectId=796122111e42, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=796122111e42, replyNumber=0, likeNumber=81, createdTime=2022-01-21, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=796122111e42, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=796122111e42)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949559, encodeId=dff8194955943, content=<a href='/topic/show?id=ed1fe5540f0' target=_blank style='color:#2F92EE;'>#突破性疗法称号#</a>, objectTitle=转移性葡萄膜黑色素瘤该如何治疗？FDA授予tebentafusp“突破性疗法称号”, objectType=article, longId=207376, objectId=04bd20e376d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04bd20e376d9, replyNumber=0, likeNumber=85, createdTime=2021-10-03, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04bd20e376d9, moduleTitle=转移性葡萄膜黑色素瘤该如何治疗？FDA授予tebentafusp“突破性疗法称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04bd20e376d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949558, encodeId=6f211949558b8, content=<a href='/topic/show?id=ed1fe5540f0' target=_blank style='color:#2F92EE;'>#突破性疗法称号#</a>, objectTitle=中国国家药品管理局（NMPA）授予sotorasib治疗晚期非小细胞肺癌“突破性疗法称号”, objectType=article, longId=206441, objectId=d25f206441fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d25f206441fe, replyNumber=0, likeNumber=81, createdTime=2021-05-27, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d25f206441fe, moduleTitle=中国国家药品管理局（NMPA）授予sotorasib治疗晚期非小细胞肺癌“突破性疗法称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d25f206441fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949554, encodeId=b1d5194955486, content=<a href='/topic/show?id=ed1fe5540f0' target=_blank style='color:#2F92EE;'>#突破性疗法称号#</a>, objectTitle=FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”, objectType=article, longId=201251, objectId=a8de201251f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8de201251f5, replyNumber=0, likeNumber=72, createdTime=2021-07-10, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8de201251f5, moduleTitle=FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8de201251f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949553, encodeId=9d641949553a9, content=<a href='/topic/show?id=ed1fe5540f0' target=_blank style='color:#2F92EE;'>#突破性疗法称号#</a>, objectTitle=口服小分子抑制剂Pritelivir获得FDA授予突破性疗法称号，用于治疗免疫功能低下的单纯疱疹病毒感染, objectType=article, longId=195480, objectId=075d1954800a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=075d1954800a, replyNumber=0, likeNumber=81, createdTime=2021-05-16, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=075d1954800a, moduleTitle=口服小分子抑制剂Pritelivir获得FDA授予突破性疗法称号，用于治疗免疫功能低下的单纯疱疹病毒感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=075d1954800a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949555, encodeId=a4a6194955575, content=<a href='/topic/show?id=ed1fe5540f0' target=_blank style='color:#2F92EE;'>#突破性疗法称号#</a>, objectTitle=IMGN632治疗复发难治囊性浆细胞样树突状细胞肿瘤：FDA授予突破性疗法称号, objectType=article, longId=201729, objectId=c1e7201e2955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1e7201e2955, replyNumber=0, likeNumber=73, createdTime=2021-07-01, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1e7201e2955, moduleTitle=IMGN632治疗复发难治囊性浆细胞样树突状细胞肿瘤：FDA授予突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1e7201e2955)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949549, encodeId=5a8219495499b, content=<a href='/topic/show?id=ed1fe5540f0' target=_blank style='color:#2F92EE;'>#突破性疗法称号#</a>, objectTitle=礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号, objectType=article, longId=190457, objectId=fbcc19045e07, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbcc19045e07, replyNumber=0, likeNumber=85, createdTime=2020-09-03, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbcc19045e07, moduleTitle=礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbcc19045e07)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949557, encodeId=56ae194955ed0, content=<a href='/topic/show?id=ed1fe5540f0' target=_blank style='color:#2F92EE;'>#突破性疗法称号#</a>, objectTitle=ViiV两月一次长效注射剂cabotegravir用于预防HIV，获得FDA的突破性疗法称号, objectType=article, longId=203543, objectId=df7b20354322, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df7b20354322, replyNumber=0, likeNumber=82, createdTime=2021-06-29, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df7b20354322, moduleTitle=ViiV两月一次长效注射剂cabotegravir用于预防HIV，获得FDA的突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df7b20354322)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949551, encodeId=9a0d19495511d, content=<a href='/topic/show?id=ed1fe5540f0' target=_blank style='color:#2F92EE;'>#突破性疗法称号#</a>, objectTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, objectType=article, longId=194130, objectId=0b9d19413073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9d19413073, replyNumber=0, likeNumber=68, createdTime=2020-09-16, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9d19413073, moduleTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9d19413073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949556, encodeId=889319495568d, content=<a href='/topic/show?id=ed1fe5540f0' target=_blank style='color:#2F92EE;'>#突破性疗法称号#</a>, objectTitle=Lanifibranor治疗NASH：FDA授予“突破性疗法称号”, objectType=article, longId=202052, objectId=b0b52020520a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0b52020520a, replyNumber=0, likeNumber=77, createdTime=2020-12-17, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0b52020520a, moduleTitle=Lanifibranor治疗NASH：FDA授予“突破性疗法称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0b52020520a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949548, encodeId=b3a4194954800, content=<a href='/topic/show?id=ed1fe5540f0' target=_blank style='color:#2F92EE;'>#突破性疗法称号#</a>, objectTitle=强生的EGFR-MET双特异性抗体JNJ-6372治疗非小细胞肺癌，获得FDA的突破性疗法称号, objectType=article, longId=189903, objectId=463418990337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=463418990337, replyNumber=0, likeNumber=84, createdTime=2020-04-02, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=463418990337, moduleTitle=强生的EGFR-MET双特异性抗体JNJ-6372治疗非小细胞肺癌，获得FDA的突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=463418990337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949550, encodeId=52c119495505f, content=<a href='/topic/show?id=ed1fe5540f0' target=_blank style='color:#2F92EE;'>#突破性疗法称号#</a>, objectTitle=肺动脉高压新药Sotatercept，获得FDA突破性疗法称号, objectType=article, longId=191907, objectId=1f2f19190e67, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f2f19190e67, replyNumber=0, likeNumber=80, createdTime=2020-10-23, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f2f19190e67, moduleTitle=肺动脉高压新药Sotatercept，获得FDA突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f2f19190e67)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1949552, encodeId=4887194955200, content=<a href='/topic/show?id=ed1fe5540f0' target=_blank style='color:#2F92EE;'>#突破性疗法称号#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, objectType=article, longId=194432, objectId=19de1944327b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19de1944327b, replyNumber=0, likeNumber=0, createdTime=2021-02-05, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19de1944327b, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19de1944327b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

突破性疗法称号

2020-05-29

jiyangfei (审核中...)

前往app查看评论内容

#突破性疗法称号#

靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌

2022-01-21

jiyangfei (审核中...)

前往app查看评论内容

#突破性疗法称号#

转移性葡萄膜黑色素瘤该如何治疗？FDA授予tebentafusp“突破性疗法称号”

2021-10-03

jiyangfei (审核中...)

前往app查看评论内容

#突破性疗法称号#

中国国家药品管理局（NMPA）授予sotorasib治疗晚期非小细胞肺癌“突破性疗法称号”

2021-05-27

jiyangfei (审核中...)

前往app查看评论内容

#突破性疗法称号#

FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”

2021-07-10

jiyangfei (审核中...)

前往app查看评论内容

#突破性疗法称号#

口服小分子抑制剂Pritelivir获得FDA授予突破性疗法称号，用于治疗免疫功能低下的单纯疱疹病毒感染

2021-05-16

jiyangfei (审核中...)

前往app查看评论内容

#突破性疗法称号#

IMGN632治疗复发难治囊性浆细胞样树突状细胞肿瘤：FDA授予突破性疗法称号

2021-07-01

仁医06 (审核中...)

前往app查看评论内容

#突破性疗法称号#

礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号

2020-09-03

jiyangfei (审核中...)

前往app查看评论内容

#突破性疗法称号#

ViiV两月一次长效注射剂cabotegravir用于预防HIV，获得FDA的突破性疗法称号

2021-06-29

jiyangfei (审核中...)

前往app查看评论内容

#突破性疗法称号#

FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌

2020-09-16

jiyangfei (审核中...)

前往app查看评论内容

#突破性疗法称号#

Lanifibranor治疗NASH：FDA授予“突破性疗法称号”

2020-12-17

仁医06 (审核中...)

前往app查看评论内容

#突破性疗法称号#

强生的EGFR-MET双特异性抗体JNJ-6372治疗非小细胞肺癌，获得FDA的突破性疗法称号

2020-04-02

jiyangfei (审核中...)

前往app查看评论内容

#突破性疗法称号#

肺动脉高压新药Sotatercept，获得FDA突破性疗法称号

2020-10-23

jiyangfei (审核中...)

前往app查看评论内容

#突破性疗法称号#

靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌

2021-02-05

科室
- - 订阅+
  - 更多科室
工具
服务